Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Colorectal Cancer: early-phase trial registry
18 of 46 indexed Metastatic Colorectal Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #312 of 28,707 conditions by registered trial count.
46 US clinical trials · 18 currently recruiting · #312 of 28,707 conditions by registered trial count
Metastatic Colorectal Cancer: 46 US clinical trials tracked, 18 recruiting.
Metastatic Colorectal Cancer is the subject of 46 registered US clinical trials on ClinicalTrials.gov, 18 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 37 in Phase 1-2 (earlier-stage). The most active sponsor is Amgen, running 3 of these trials.
Enrollment posture brief
Registry condition metastatic-colorectal-cancer
OPEN 18 | RECR 39% | LATE 4 | EARLY 37 | RANK #312 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Advanced Non-Small-Cell Lung Cancer (39% recruiting · 23 trials)
Metastatic Colorectal Cancer lists 18 open slots (39% of 46 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Colorectal Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Colorectal Cancer recruits in line with its size-band peers.
18 of 46 indexed trials (39.1%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Metastatic Colorectal Cancer trials is spread across many organizations.
Amgen accounts for 3 of 46 trials (6.5%). 35 distinct sponsors appear on at least one study for this condition label.
-
Typical Metastatic Colorectal Cancer enrolment sits around 102 participants.
Median target enrolment is 102 among the 46 trials that report a genuine target (sentinel values excluded). 23 of those (50%) plan for fewer than 100 participants.
-
Metastatic Colorectal Cancer research is mostly interventional.
45 interventional and 1 observational studies make up this index (97.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
46 total, page 1 of 1
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Hoffmann-La Roche
NCT04929223
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
BioNTech SE
NCT07079631
A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
AbbVie
NCT06614192
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Amgen
NCT06252649
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Artios Pharma
NCT04657068
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
NCT06625775
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
AbbVie
NCT06820463
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
National Cancer Institute (NCI)
NCT01174121
Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
Riboscience
NCT06824064
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
AstraZeneca
NCT06792695
Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
NCT06959550
Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial
Dana-Farber Cancer Institute
NCT06202183
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
National Cancer Institute (NCI)
NCT06149481
Couple-Based Mindfulness Intervention for Metastatic Colorectal Cancer
University of Colorado, Denver
NCT05840263
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
H. Lee Moffitt Cancer Center and Research Institute
NCT06553885
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
M.D. Anderson Cancer Center
NCT06412198
Trial of ProAgio in Advanced/Metastatic Colorectal Cancer
University of Alabama at Birmingham
NCT06867822
Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
M.D. Anderson Cancer Center
NCT05985954
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
Bristol-Myers Squibb
NCT04008030
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
OncoC4
NCT04140526
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Mirati Therapeutics
NCT04793958
A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer
Akeso
NCT05382442
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
Agenus
NCT05608044
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
Cardiff Oncology
NCT06106308
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
Pfizer
NCT05217446
A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
Erasca
NCT05039177
Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer
Amal Therapeutics
NCT04046445
Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
University of Wisconsin, Madison
NCT04587128
Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
University of Wisconsin, Madison
NCT05854498
Pressure-enabled Delivery in Radioembolization (TriNav Study)
Massachusetts General Hospital
NCT05128032
An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.
Arcus Biosciences
NCT04660812
Improving Informed Consent for Palliative Chemotherapy
Dana-Farber Cancer Institute
NCT02282722
Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer
Amgen
NCT00625651
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
Novartis Pharmaceuticals
NCT01576666
Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)
Merck Sharp & Dohme
NCT03374254
Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer
Memorial Sloan Kettering Cancer Center
NCT01312857
Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients
Memorial Sloan Kettering Cancer Center
NCT02437071
A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer
Anuradha Krishnamurthy
NCT02260440
Immunotherapy for Third Line Metastatic Colorectal Cancer
Mirror Biologics
NCT04444622
Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma
University of Wisconsin, Madison
NCT00574171
Effect of Panitumumab on the Pharmacokinetics of Irinotecan
Amgen
NCT00563316
Regorafenib in Metastatic Colorectal Cancer
University of Rochester
NCT02466009
SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01966289
A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients
University of Chicago
NCT01183494
EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options
Dana-Farber Cancer Institute
NCT03602885
A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer
OncoMed Pharmaceuticals
NCT03031691
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 19 |
| Phase 2 | 18 |
| Phase 3 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Colorectal Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Colorectal Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Colorectal Cancer page
46 registered trials, 18 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 18 Metastatic Colorectal Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Amgen sponsors the most Metastatic Colorectal Cancer trials on record, review their full trial history before evaluating a specific study. See Amgen's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Colorectal Cancer condition card totals 46 registered trials; most-linked intervention Bevacizumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.